Premium
Evaluating anti‐β‐Catenin monoclonal antibodies for cancer diagnosis and prognosis
Author(s) -
Lu Hsiangmin Emily,
Fu Wei,
Yuan Kehu,
Chu Boyang,
Wang Guangli,
Shu Youmin,
He Weiwu,
Ma Donghui
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.417.10
Subject(s) - colorectal cancer , monoclonal antibody , wnt signaling pathway , antibody , immunohistochemistry , medicine , cancer , catenin , cancer research , antibody microarray , carcinogenesis , tissue microarray , monoclonal , oncology , immunology , biology , signal transduction , genetics
Colorectal cancer is one of the most common cancers and ranks second in mortality in the US. Wnt/β‐Catenin signaling pathway plays an important role in colorectal cancer, and the mutation events have been studied the most for colorectal carcinogenesis. However, other studies have shown the nuclear translocation of β‐Catenin could be an additional factor for clinical diagnosis of colorectal cancer. Therefore, it is essential to develop the monoclonal antibody with the highest sensitivity and specificity. Even though there are many monoclonal antibodies being used for β‐Catenin studies, they have not been carefully examined for potential cross‐reactivity which could cause false diagnosis. To develop the most suitable monoclonal antibody for β‐Catenin studies, we used different immunoassays to validate the specificity and sensitivity of the commercially available antibodies. By the high density protein microarray chip technology and other assays, we identified that β‐Catenin UltraMAB antibody can be used for different applications in basic research. Furthermore, we used immunohistochemistry with tissues from colorectal cancer patients and showed that β‐CateninUltraMAB antibody is a great tool for potential cancer diagnosis and prognosis.